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Abstract
Background: Humoral immune responses in human immunodeficiency virus (HIV)-infected and uninfected children
with Pneumocystis pneumonia (PcP) are poorly understood.
Methods: Consecutive children hospitalized with acute pneumonia, tachypnea, and hypoxia in South Africa were
investigated for PcP, which was diagnosed by real-time polymerase chain reaction on lower respiratory tract
specimens. Serum antibody responses to recombinant fragments of the carboxyl terminus of Pneumocystis jirovecii
major surface glycoprotein (MsgC) were analyzed.
Results: 149 children were enrolled of whom 96 (64%) were HIV-infected. PcP occurred in 69 (72%) of HIV-infected
and 14 (26%) of HIV-uninfected children. HIV-infected children with PcP had significantly decreased IgG antibodies
to MsgC compared to HIV-infected patients without PcP, but had similar IgM antibodies. In contrast, HIV-uninfected
children with PcP showed no change in IgG antibodies to MsgC, but had significantly increased IgM antibodies
compared to HIV-uninfected children without PCP. Age was an independent predictor of high IgG antibodies,
whereas PcP was a predictor of low IgG antibodies and high IgM antibodies. IgG and IgM antibody levels to the most
closely related MsgC fragments were predictors of survival from PcP.
Conclusions: Young HIV-infected children with PcP have significantly impaired humoral immune responses to
MsgC, whereas HIV-uninfected children with PcP can develop active humoral immune responses. The children also
exhibit a complex relationship between specific host factors and antibody levels to MsgC fragments that may be
related to survival from PcP.
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Introduction
Pneumocystis jirovecii is an opportunistic pulmonary
pathogen of worldwide distribution. Primary P. jirovecii infection
is acquired during the first few months of life, and is either
asymptomatic or a self-limited infection [1,2].
Seroepidemiological studies have shown that by 2-3 years of
age, most healthy children have been infected with the
organism [2-6]. P. jirovecii remains a major cause of life-
threatening pneumonia (termed “PcP”) in children who are
immunocompromised by human immunodeficiency virus (HIV)
infection, cancer, or other disorders. This is especially true in
children in low or middle income countries where the disease
occurs in 10% to 49% of HIV-infected children hospitalized for
pneumonia with an in-hospital mortality rate of 20% to 63%
[7-11].
The diagnosis of PcP has traditionally been made by the
demonstration of the organism by histologic or
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immunofluorescent staining in specimens that have been
carefully obtained from the respiratory tract. It is likely that this
method underestimates the true incidence of PcP, particularly
in areas with limited laboratory facilities [1-14]. Recent studies
in adults with and without PcP have shown that the polymerase
chain reaction (PCR), particularly real time (RT)-PCR, is more
sensitive than microscopy in detecting P. jirovecii and may also
distinguish colonization from active disease [15-21]. We have
obtained similar results with the use of RT-PCR in the
diagnosis of PcP and tuberculosis in young children [22-24].
HIV-infected children with PcP have markedly decreased
CD4+ cell counts and broad defects in cellular and humoral
function, as illustrated by their low serum antibody levels to
common infectious agents and to immunizations [25-28]. HIV-
uninfected children, who are exposed to HIV but remain HIV-
negative, have been reported to be at greater risk for
developing PcP than HIV-uninfected, unexposed children
[29,30]; however, the reasons for the difference are unclear
[31-34].
Little is known about the role of specific immune responses
to P.jirovecii in HIV-infected children with or without PcP. Over
the past decade, the development of recombinant antigens has
begun to change this picture. The major surface glycoprotein
(Msg) of P.jirovecii plays a central role in the interaction of the
organism with the host; contains protective B and T cell
epitopes; is encoded by a multi-gene family, and is capable of
antigenic variation [35-39]. We have developed 3 recombinant
fragments (MsgA, MsgB, MsgC1) that span the length of a
single Msg isoform [23], and analyzed their reactivity in both
adult and pediatric populations [6,40-48]. MsgC1, which
contains the carboxyl terminus and is the most conserved part
of Msg, showed the most promise; thus, 3 variants (MsgC3,
MsgC8, and MsgC9) were developed to better characterize the
reactivity of the antibodies [40-48].
The aims of this study were: 1) to characterize the IgG and
IgM antibody responses to MsgC fragments in HIV-infected
and HIV-uninfected children hospitalized with PcP (PcP+) and
other causes of pneumonia (PcP-); 2) to identify specific host
factors that are independent predictors of these antibody
levels; 3) to determine if any of the antibody responses are
independent predictors of mortality from PcP.
Materials and Methods
Study Design
A prospective study was conducted of consecutive children
admitted to the Red Cross War Memorial Children’s Hospital,
Cape Town, South Africa, with hypoxic pneumonia from Nov
2006 to Aug 2008 [22]. Clinical criteria for suspected PCP were
an acute onset (<2 weeks) of a respiratory illness; the presence
of age-specific tachypnea and hypoxia (arterial oxygen
saturation <92% in room-air); bilateral lung disease (not
associated with wheezing); and the presence of a risk factor for
PCP (e.g. HIV-infection, malnutrition, immunosuppressive
therapy). These criteria were established to ensure that
subjects were seriously ill with pneumonia and had significant
risk factors for PCP. Initial specimens were obtained within the
first 48 hours of admission. Exclusion criteria included
treatment of PcP in the preceding 2 weeks or treatment for
PCP for the current admission for more than 48 hours.
Blood specimens were collected at enrollment for HIV testing
(if status was unknown), CD4 cell measurement, and a serum
specimen was frozen for further analysis. A child was defined
as HIV-infected if he/she had a positive HIV PCR (Roche) and
was younger than 18 months or a positive HIV ELISA for
antibodies (Abbott) in older children. HIV exposure was defined
as HIV-seropositive by ELISA and negative by HIV PCR.
Upper respiratory tract (URT) specimens were obtained from
nasopharyngeal aspirates (NPAs) and lower respiratory tract
(LRT) specimens by induced sputum (IS) or bronchoalveolar
lavage (BAL) in a standard manner within 48 hours of
admission. The specimens were examined for the presence of
P. jirovecii by RT-PCR and microscopic techniques (direct
immunofluorescence (IF) using a monoclonal antibody, silver
staining) and other organisms as described (23). The data
showed that RT-PCR was far more sensitive than microscopic
techniques in detecting P. jirovecii with good specificity. Other
organisms that were found included viruses (e.g.
cytomegalovirus (CMV), respiratory viruses) and bacteria (e.g.
Staphylococcus aureus, Mycobacterium tuberculosis).
Treatment of PcP included trimethoprim-sulfamethoxazole
(TMP-SMX) and corticosteroids; other antimicrobial drugs, or
antiretroviral drugs were at the discretion of the treating
physician. The overall in-hospital mortality rate was 25%, and
the case-fatality rate was also significantly higher in PcP
patients (40%) than in non-PcP patients (21%). Written
informed consent was obtained from a parent or legal guardian.
Ethical approval of the study was obtained from the Research
and Ethics Committee of the Faculty of Health Sciences,
University of Cape Town and the University of Cincinnati
Institutional Review Board
Recombinant Antigens
The DNA fragments containing genes encoding recombinant
MsgC1, C3, C8, and C9 fragments were prepared via PCR
using DNA isolated from P. jirovecii- infected lung or cloned
msg genes as templates as described [40-42]. Each of the 4
MsgC fragments included approximately 425 amino acids. The
fragments exhibited 83 to 99% homology at the nucleotide level
and 77 to 99% homology at the putative amino acid level [41].
MsgC3 and MsgC9 were the most closely related fragments
with just 3 amino acid substitutions.
ELISA
The IgG ELISA was performed as previously described
[40-42]. Serum specimens to be analyzed and the standard
reference serum were tested against each MsgC fragment. The
standard specimens were obtained by testing banks of sera
from blood donors and HIV-infected patients. The standard
serum for each antigen consisted of a pool of 4 to 6 serum
specimens with high antibody reactivity to that antigen. The
standard serum was defined as having a value of 100 U in 100
µl of a 1:100 dilution. We used the same standard pools
throughout the study, and as a further measure to ensure
consistency between assays, we titrated subsequent standard
pools against those initial standards. From the standard pool,
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we generated a standard curve for each Msg construct on each
day the assay was used. We used this curve to calculate the
units of reactivity to the Msg construct. We diluted test serum
samples at 1:100 to 1:200 to fit the linear portion of the curves.
Taking into account the dilution, we then calculated units of
reactivity [40-42].
IgM antibodies were analyzed in a similar manner except
that an anti-IgM (µ-specific) antibody was used [5]. Variations
in the assay results were analyzed using a control serum and
were measured for MsgC1 on a per-plate, daily, and 4 day
basis; the coefficients of variance (CV) were 3.6 to 7%, 4.8 to
7.4%, and 13.3%, respectively [41].
Data Analysis and Statistics
In the first part of the analysis, we characterized the children
as follows: HIV-infected with PcP (PcP+), HIV-infected with
other causes of pneumonia (PcP-), HIV-uninfected with PcP
(HIV-uninfected/PcP+), and HIV-uninfected without PcP (HIV-
uninfected/PcP-). We used medians (interquartile range) or
counts (percent) to describe continuous and discrete
characteristics, respectively. In the second part of the analysis,
quantile regression analysis was employed to compare
antibody levels among groups and to determine independent
risk factors associated with antibody levels. In our previous
publications, means of log-transformed antibody responses to
Msg fragments were modeled using Tobit regression, as the
transformed uncensored responses approximated a truncated
lognormal distribution [6,41-45]. In the present study, however,
although some subjects had antibody levels below the limit of
detection and the values were censored to “1’, we chose to use
Quantile regression. This strategy was primarily due to the
large number of extremely high antibody responses which
precluded modeling the mean response, even after log-
transformation. Quantile regression is a non-parametric method
which models the relation between a set of independent
variables and conditional quantiles (percentiles) of the
dependent variable [49]. Quantile regression has also been
used to analyze immunological data with high frequency of
undetectable results or “non-detects” [50]. Eilers et al. showed
that quantile regression permitted groups to be compared and
meaningful linear trends could be computed even though more
than 50% of the data was composed of non-detects. In the
present study, 29% of antibody responses to MsgC1, 32% to
MsgC3, 16% to MsgC8, and 19% to MsgC9 were censored.
Since non-censored antibody levels in the present study
were in the upper quartiles, we compared the groups in the
75th and 90th quantiles, and then determined the factors
associated with these conditional percentiles. In the final stage
of the analysis, we determined predictors of PCP-related
mortality using Cox proportional hazard models. The analysis
included HIV+ children with PCP and HIV- children with PCP.
SAS for Windows, version 9.2 (SAS Institute, Cary, NC) was
used to carry out all statistical analyses, and a 5% significance
level was assumed, unless stated otherwise.
Results
Demographic and Clinical Characteristics
Of the 202 children originally enrolled (17), 149 (73%) were
included in the present study: 96 (64%) were HIV-infected of
whom 69 (72%) had PcP+ (Table 1). These children differed
significantly from the HIV-infected/PcP- children in their
younger age; lower proportion receiving PcP prophylaxis;
greater level of immunosuppression as measured by CD4+ cell
count; and greater lung damage as evidenced by higher LDH
levels. There was also a trend towards higher mortality.
Of the 53 HIV-uninfected patients, 21 (40%) were HIV-
exposed. Of the exposed patients, only 3 (14%) had PcP,
whereas 11 (34%) of the 32 unexposed patients had PcP.
There were no significant differences in demographic or clinical
characteristics between HIV-uninfected/PcP+ and HIV-
uninfected/PcP- children (Table 1).
Table 1. Descriptive Characteristics of the Children at Enrollment.
 HIV+ (N = 96) HIV- (N=53) All (N=149
Characteristics PcP+ (n=69) PcP- (n=27) PcP+ (n=14) PcP- (n=39) HIV+ (n=96) HIV- (n=53)
Age (months) 3.4 (2.7-4.0) 5.3 (1.9-10.0) 3.0 (2.5-3.6) 2.2 (1.2-6.9) 3.5 (2.7-4.7) 2.5 (1.3-4.1)
Male 23 (33) 14 (52) 9 (64) 19 (49) 37 (39) 28 (53)
CD4 (cells/µl) 296 (118-590) 546 (263-934)   309 (129-709)  
HIV RNA (x106 copies/mL) 2.9 (0.58-3.0) 2.5 (0.79-3.0)   2.6 (0.58 -3.0)  
ART 42 (55) 15 (33)   57 (59)*  
Breast Feeding 35 (53) 14 (61) 8 (57) 19 (52) 49 (55) 27 (54)
Intubation 1 (4) 1 (1) 1(7) 3 (8) 2 (2) 4 (8)
PcP Prophylaxis 9 (13) 10 (34) 1 (7) 3 (8) 19 (20) 4 (8)
LDH (U/L) 729 (556-1152) 532 (290-686) 487 (432-675) 353 (236-418) 671 (527-1028) 377 (236-610)
Weight (kg) -for-Age Z Score 4.4 (3.6-5.2) 5.6 (4.0-6.2) 3.6 (3.2-4.5) 4.3 (2.9-6.8) 4.6 (3.7-5.5) 3.9 (3.1-4.9)
Mortality 24 (35) 7 (26) 0 (0) 5 (13) 31 (32) 5 (9)
Continuous and Discrete Data Were Expressed as Median (IQR) and Count (% N), Respectively.
Note: Bolded values are significantly different. * Proportion of HIV-infected patients on ART = antiretroviral therapy. LDH = serum lactate dehydrogenase. HIV+ = HIV-
infected. HIV- = HIV-uninfected
doi: 10.1371/journal.pone.0082783.t001
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Serum IgG and IgM Antibody Levels
HIV-infected/PcP+ patients had significantly lower IgG
antibody levels than HIV-infected/PcP- patients to MsgC1 in
the 90th percentile; to MsgC3 in the 75th and 90th percentiles;
and to MsgC8 in the 90th percentile (Table 2). In contrast, no
significant differences were seen in IgG antibody levels to the
MsgC fragments between HIV-uninfected/PcP+ and HIV-
uninfected/PcP- children or between HIV-infected/PcP+ and
HIV-uninfected/PcP+ children (Table 2). There were also no
significant differences in IgG antibody levels between all HIV-
infected and all HIV-uninfected children (data not shown).
No significant differences were found in IgM antibody levels
to any of the MsgC constructs among HIV-infected/PcP+ or
HIV-infected/PcP- subjects (Table 3). By contrast, HIV-
uninfected/PcP+ patients had significantly higher IgM antibody
levels than HIV-uninfected/PcP- patients to MsgC1, C8, and C9
in the 75th percentile (Table 3). We were unable to compare
antibody levels between HIV-uninfected, exposed, PcP+ and
PcP- children due to the small number (3) of PcP+ children.
Table 2. Estimated 75th and 90th Percentiles [SE] of IgG
Antibody Responses to MsgC Fragments by PcP Diagnosis
among HIV+ and HIV- Children at Enrolment.
  HIV+ HIV-
Antigens Percentile PcP+ (N=69) PcP- (N=27) PcP+ (N=14) PcP- (N=39)
MsgC1 75th 1.00 [0.0] 76.78 [16.0] 3.35 [17.2] 14.35 [12.0]
MsgC1 90th 3.88*[6.4] 121.59* [17.0] 23.97 [46.3] 76.01[25.2]
MsgC3 75th 1.00*[2.3] 174.27*[62.2] 24.27 [48.9] 4.37 [2.8]
MsgC3 90th 18.53* [18.0] 250.90* [55.6] 141.26 [72.7] 32.14 [27.2]
MsgC8 75th 1.00 [0.0] 21.77 [49.1] 3.85 [20.3] 1.00 [0.4]
MsgC8 90th 1.00* [8.0] 287.47* [130.8] 36.25 [53.0] 4.77 [16.0]
MsgC9 75th 1.00 [0.3] 3.10 [31.9] 16.10 [55.2] 1.00 [2.5]
MsgC9 90th 8.86 [10.9] 181.03 [134.9] 153.89 [79.7] 13.27 [12.9]
* The groups are significantly different. SE = Standard error. HIV+ = HIV-infected.
HIV- = HIV-uninfected
doi: 10.1371/journal.pone.0082783.t002
Table 3. Estimated 75th and 90th Percentiles [SE] of IgM
Antibody Responses to MsgC Fragments by PcP Diagnosis
among HIV+ and HIV- Children at Enrolment.
  HIV+ HIV-
Antigens Percentile PcP+ (N=69) PcP- (N=27) PcP+ (N=14) PcP- (N=39)
MsgC1 75th 49.54 [10.7] 50.97 [42.3] 109.64 [41.0] 20.66 [9.0]
MsgC1 90th 100.72 [14.0] 202.93 [91.3] 126.94 [19.0] 88.60 [41.1]
MsgC3 75th 10.76 [3.6] 9.55 [2.7] 13.21 [10.1] 1.48 [1.8]
MsgC3 90th 27.65 [5.6] 18.62 [6.9] 36.15 [9.7] 7.66 [2.6]
MsgC8 75th 10.84 [3.8] 9.70 [4.1] 18.27 [9.7] 1.21 [0.9]
MsgC8 90th 27.65 [4.2] 15.80 [12.3] 33.02 [9.9] 5.37 [6.3]
MsgC9 75th 6.41 [2.2] 5.60 [1.6] 18.72* [11.3] 4.06* [1.8]
MsgC9 90th 17.73 [3.3] 10.02 [2.4] 25.20 [31.7] 8.14 [3.5]
* The groups are significantly different. SE = Standard error. HIV+ = HIV-infected.
HIV- = HIV-uninfected SE:
doi: 10.1371/journal.pone.0082783.t003
Predictors of IgG and IgM Antibody Responses
Regression analyses were performed to find correlations
between host factors and antibody responses. Of the IgG
antibody responses, age was a predictor of high antibody
levels to MsgC1 in the 75th percentile and PcP was a predictor
of low antibody levels to MsgC1 in the 75th and the 90th
percentiles (Table 4). Age was also a predictor of high antibody
levels to MsgC3, MsgC8, and MsgC9 in the 75th percentiles. Of
the IgM antibody responses, PcP was a predictor of high
antibody levels to MsgC3 in the 75th and 90th percentiles, and to
MsgC9 in the 90th percentile (Table 5).
IgG and IgM Antibody Responses as Predictors of PcP-
related Mortality
Antibody levels to each MsgC construct, weight, and age
were analyzed as predictors of PcP-related mortality using HIV
Table 4. Predictors of IgG Antibody Responses to MsgC
Fragments.
  75th Percentile 90th Percentile
Antigens Characteristics Estimate p-value Estimate p-value
MsgC1 Age 1.35 <0.01 0.35 0.71
 PcP -2.83 <0.01 -2.66 <0.01
 HIV 0.00 1.00 -0.19 0.80
MsgC3 Age 4.08 <0.01 1.90 0.19
 PcP -0.81 0.33 -0.65 0.43
 HIV -0.95 0.25 -0.61 0.51
MsgC8 Age 3.04 <0.01 3.47 0.13
 PcP -0.00 1.00 -0.91 0.45
 HIV -0.00 1.00 -1.35 0.31
MsgC9 Age 2.11 0.03 1.76 0.48
 PcP 0.00 1.00 -0.08 0.95
 PcP Prophylaxis -0.00 1.00 -0.32 0.82
doi: 10.1371/journal.pone.0082783.t004
Table 5. Predictors of IgM Antibody Responses to MsgC
Fragments.
  75th Percentile 90th Percentile
Antigens Characteristics Estimate p-value Estimate p-value
MsgC1 Age -0.37 0.38 -0.89 0.06
 PcP 0.49 0.29 -0.41 0.15
 HIV 0.37 0.26 -0.05 0.86
MsgC3 Age 0.71 0.25 0.90 0.12
 PcP 1.16 0.02 1.19 <0.01
 HIV 0.82 0.14 -0.01 0.99
MsgC8 Age -0.41 0.57 -0.26 0.70
 PcP 1.08 0.06 0.67 0.06
 HIV 0.70 0.21 0.01 0.97
MsgC9 Age 0.25 0.66 0.13 0.82
 PcP 0.74 0.08 0.84 <0.01
 PcP Prophylaxis -0.26 0.54 -0.20 0.50
doi: 10.1371/journal.pone.0082783.t005
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+ with PcP and HIV- with PcP and the results were expressed
as the Adjusted Mortality Risk Ratios (RR). Of the IgG
antibodies, only the antibody level to MsgC3 approached
significance: RR 0.58, 95%CI [0.34-1.00] p= 0.05. Of the IgM
antibodies, only the antibody level to MsgC9 was significant:
RR 0.64, 95% CI [0.41-0.99] p< 0.05. Thus, the IgG antibody
level to MsgC3 and IgM antibody level to MsgC9 were
associated with a 36.7% and 39% decrease in PcP-related
mortality, respectively. In the sensitivity analysis using only HIV
+ children with PCP, the effect of CD4+ cell count on mortality
was not statistically significant.
Discussion
This study has shown that hospitalized HIV-infected children
with PcP (PcP+) had significantly lower serum IgG antibodies
to recombinant MsgC fragments than HIV-infected children with
pneumonia due to other causes (PcP-). By contrast, HIV-
uninfected PcP+ children had significantly higher IgM
antibodies to these fragments than HIV-uninfected PcP –
patients. Age was a predictor of high IgG antibodies, whereas
PcP was a predictor of low IgG antibodies but high IgM
antibodies. IgG antibody levels to MsgC3 and IgM antibody
levels to MsgC9 also were associated with a reduced mortality
from PcP.
Studies of the humoral and cellular immune responses to a
specific respiratory pathogen in any patient with pneumonia
depend on accurate etiological diagnosis. Recent reports
showing that RT-PCR is more sensitive than microscopic
analysis in diagnosing PcP in adults [15-21] and children [23]
are important because they increase the number of subjects
available for analysis and can also distinguish P. jiroveci
colonization from disease. HIV-infected children not only have
broad immune defects ranging from low CD4 counts to B-cell
dysregulation with hyperimmunoglobulinemia, but also have
poor antibody responses to specific infectious agents or
immunizations [25-28,51,52]. Impaired placental transfer of
antibodies from HIV-infected mothers is an important
contributor to these poor specific antibody responses, as has
been shown with viral, bacterial, and parasitic antigens [53,54].
Since maternal antibodies are the main source of protective
humoral immune responses during the first 6 months of life, it is
not surprising that many of these infections occur during this
time.
Our HIV-infected/PcP+ children exhibited many of the
characteristics described above, including low CD4+ cell
counts, development of PcP at age 3-4 months, severe
disease, elevated LDH levels, low fraction of patients receiving
chemoprophylaxis, and a high mortality rate. These children
also had very low serum IgG antibody levels to the MsgC
fragments, and were unable to develop an active IgM antibody
responses that could distinguish them from HIV-infected/PcP-
children.
In contrast to these young HIV-infected children, adult HIV-
infected patients with active PcP or a previous episode of PcP
whom we have studied display higher antibody levels to the
MsgC fragments than HIV-infected patients who never had PcP
or healthy adults [43]. HIV-infected adults hospitalized with
active PcP had significantly higher levels of IgM and IgG
antibody levels than HIV-infected adults hospitalized with other
causes of pneumonia at the time of diagnosis, and the
differences in antibody levels were maintained until 3-4 weeks
later [45]. The positive predictive values (PPV) for IgG and IgM
antibody levels rose from 71.5% and 79.3% at admission to
100% and 89.8%, respectively, at 3-4 weeks. It is likely that
most HIV-infected adults have fully developed immune systems
and repeated exposures to P. jirovecii throughout their lives
before they develop PcP, whereas young HIV-infected children
have immature immune systems and lesser cumulative
exposure to P. jirovecii.
The MsgC fragments used in the present and previous
reports exhibited a high degree homology, and thus have
shared as well as unique antigenic determinants. If one MsgC
fragment elicits a good antibody response, other fragments
also usually elicit good responses; on the other hand, the
MsgC fragments react independently and also have unique
epitopes (Refs 41-43). Our previous studies in HIV-infected
adults have identified specific host and environmental factors
that are independent predictors of antibody levels to one or
more of the MsgC fragments [42-44]. Thus, current PcP,
previous episode of PcP, age, failure to take PcP
chemoprophylaxis, and geographic location have been
associated with increased IgG and /or IgM antibody levels,
whereas smoking and high LDH levels have been associated
with decreased IgG and/or IgM antibody levels [6,43-45].
The present study showed age was independently
associated with increased IgG antibody levels, but not to IgM
antibody levels. It is likely that similar to antibody responses to
other commonly encountered organisms, IgG antibody levels
increase on repeated exposure to P. jirovecii antigens, as
children grow and mature. On the other hand, PcP was
associated with low IgG antibody levels to MsgC1, which
probably reflects the decreased IgG antibody levels that are
maternally derived in the HIV-infected/PcP+ patients. The
association of PcP with high IgM antibody levels to MsgC3 and
MsgC9 probably reflects the antibody response to PcP in the
HIV-uninfected/PcP+ children and the fact that MsgC3 and
MsgC9 are closely related.
HIV-uninfected exposed children in the present study had
similar, though less severe immune defects (including antibody
responses to specific antigens) than HIV-infected children
[31-34]. Low antibody levels in HIV-infected mothers and
decreased placental transmission of antibodies in HIV-infected
exposed infants have played an important role. Yet, when
tested at age 16 months following vaccination, antibody
responses in HIV- uninfected exposed children were as high as
or higher than those in the unexposed children [34].
Our HIV-uninfected/PcP+ children had serum IgG antibody
levels to the MsgC fragments that were similar to the antibody
levels in HIV-uninfected/PcP- patients. However, the HIV-
uninfected/PcP+ children exhibited significantly greater IgM
antibody responses to the MsgC fragments than the HIV-
uninfected/PcP- children. This finding suggests that HIV-
uninfected children can develop an active antibody response to
PcP. We were surprised to find that only 3 (14%) HIV-
uninfected, exposed children developed PcP, compared with
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11 (34%) of unexposed children. The reasons for this are
unclear, but risk factors other than HIV infection may have
played a role in the development of PcP. Case reports have
suggested that HIV–uninfected exposed children are also at
increased risk for the development of PcP or other lower
respiratory infections [29,30,34].
Some experimental studies have shown that Msg contains
protective B and T cell antigenic determinants [36-38], but
other reports using different models did not confirm these
observations [55]. A recent prospective study we conducted of
550 adult HIV-infected and HIV-uninfected patients hospitalized
with cough >2 weeks in Kampala, Uganda showed that lower
serum IgM antibody responses to MsgC3 and MsgC8 were
both associated with increased in-hospital mortality (48). In the
current study, we found that increased IgG antibody levels to
MsgC3 and IgM antibody levels to MsgC9 were associated with
a reduction in PcP-related mortality. Taken together, the results
of these two studies have led us to hypothesize that these
antibodies are protective or contribute to the protection from
severe PcP.
This study has several limitations. We did not determine
whether the defect in PcP antibodies was limited to this
organism or whether it was part of a broader global defect in
antibody production associated with HIV infection. Further
studies of the functional properties of these antibodies and of
the serologic responses to other infectious agents are needed.
Another limitation of this study is that it is a cross-sectional
study. Longitudinal studies in HIV-infected children are needed
to better understand the immune responses to this organism
over time, and the factors that affect these responses. The
present report only analyzed systemic antibody responses.
Further analysis of local (respiratory tract) antibody responses
and interactions between native Msg variants present in the
cell wall of P. jirovecii would be of interest. Although we found
RT-PCR to be sensitive and specific for PcP, further studies in
other pediatric populations are needed. The small number of
HIV-uninfected, exposed children with PcP precluded
evaluation of the effects of HIV exposure on development of
PcP. Additional investigation of larger numbers of these
individuals would be very helpful.
In summary, this study provides new information about the
humoral immune responses of young HIV-infected and HIV-
uninfected children to P. jirovecii antigens, and suggests future
areas for investigation.
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